Abstract
Background The eastern parts of Ethiopia, including Dire Dawa City, have faced annual dengue fever (DF) outbreaks since 2013, resulting in substantial healthcare and economic consequences. However, there remains a lack of comprehensive evidence regarding the specific dengue virus (DENV) serotypes and genotypes associated with those outbreaks.
Methodology On December 14, 2023, the National Arbovirus Laboratory at the Ethiopian Public Health Institute received seventy serum samples from 70 patients suspected of DF during the outbreak in Dire Dawa City. Samples positive for DENV with adequate volume and CT values underwent sequencing of the CprM region of the DENV genome. The obtained sequences were typed using the Dengue Virus Typing Tool and underwent phylogenetic analysis to evaluate sequence diversity and relationships to DENV strains from other global DENV-endemic regions.
Results Overall, 32 (45.7%) of the patients displayed one or more early warning signs indicative of severe dengue. Among the 13 patients who were hospitalized for 2 to 10 days, all except two had at least one symptom indicative of severe dengue. Out of 67 samples with adequate volume, 44 (65.6%) were positive for DENV RNA using RT-PCR, and 21 successfully underwent CprM sequencing. All of them belonged to DENV-3, genotype III, major lineage B (DENV-3III_B), but represented two different minor lineages (DENV-3III_B.2 and DENV-3III_B.3). Phylogenetic analysis demonstrated that both lineages were closely related to sequences from the Afar region of Ethiopia collected in 2023, indicating that the outbreaks were related and were due to multiple co-circulating lineages.
Conclusions DENV-3III_B was identified as the cause of the 2023 DF outbreak in Dire Dawa City. The identification of two co-circulating lineages in this outbreak underscores the complex nature of DENV transmission in the African continent and highlights the need for increased viral genomic surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As our study aimed to better understand DENV strains linked to DF outbreaks, we obtained an ethical approval waiver (protocol number: PO-036-24) from the All-African Leprosy Rehabilitation and Training Center/Armauer Hansen Research (ALERT/AHRI) Ethics Committee. Additionally, we obtained permission from the Dire Dawa City Health Bureau and health facilities’ authorities to investigate these outbreak samples. Since the samples used in this study were obtained from the dengue outbreak during the 2023 outbreak investigation and confirmation undertaken to respond to and control the public health emergencies, no informed consent was obtained during the sample collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
